BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 1, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Color Health Inc.’s genomics kit.

Color valuation reaches $4.6B with vibrant $100M series E

Nov. 9, 2021
By Annette Boyle
Color Health Inc. followed its rainbow to another pot of gold, collecting $100 million in a series E financing round led by Kindred Ventures and funds advised by T. Rowe Price Associates Inc. Returning funding round participants also included General Catalyst, the company’s long-time lead investor, Viking Global Investors and Emerson Collective. With the latest cash infusion, the company’s total funds raised to date reached $378 million and its valuation of $4.6 billion propelled it into the top dozen health care unicorns. Founded in 2017 as Color Genomics, the Burlingame, Calif.-based company has raised more than two-thirds of its total funding this year with today’s series E following the close of a $167 million series D round in January.
Read More

Financings for Nov. 9, 2021

Nov. 9, 2021
Med-tech firms raising money in public or private financings, including: Beacon Biosignals, Sirona Medical, Surgery Partners.
Read More

Financings for Nov. 9, 2021

Nov. 9, 2021
Biopharmas raising money in public or private financings, including: Alltrna, Amyris, Ani, Asgard, Chinook, Evotec, Home, IO, Ocuterra, Oramed, Xortx.
Read More
South Korean won

Geninus endures rocky start in Korean Stock Exchange debut, but raises $34M

Nov. 8, 2021
By Gina Lee
Geninus Inc. endured a difficult debut on Korea Exchange’s Kosdaq board, but still raised ₩40 billion (US$33.83 million) through its listing. The 2 million shares on offer tumbled 25.56% at ₩13,400 (US$11.33) at the close of trading on Nov. 8, after Geninus priced them at ₩20,000.
Read More

Quantumdx receives $20M equity investment to build on its pandemic-driven product line

Nov. 8, 2021
By Nuala Moran
LONDON – PCR point of care testing specialist Quantumdx Group Ltd. is poised to accelerate its commercial development in China, after the Hong Kong venture capital fund Vita Spring made a £15 million (US$20.3 million) equity investment.
Read More
Hand holding gear, dollar sign

Autolus revives fortunes with monster $250M investment from Blackstone

Nov. 8, 2021
By Richard Staines
After a shaky start to the year, Autolus Therapeutics plc has revived its fortunes, with Blackstone Life Sciences investing up to $250 million to fund its CAR T-cell technology and lead product targeting acute lymphoblastic leukemia.
Read More
Zhen Su, CEO, Marengo Therapeutics

Marengo closes $80M A round to harness novel antibody-mediated T-cell activation for cancer

Nov. 8, 2021
By Cormac Sheridan
Marengo Therapeutics Inc. is opening up a new front in the war on cancer by selectively deploying a tumor-infiltrating subpopulation of T cells, which can be activated by a newly identified, antibody-based mechanism. The Cambridge, Mass.-based company is taking forward a scientific concept that has been germinating for several years at founding investor and company creator ATP, which has now launched the firm with an $80 million series A round. Marengo is gearing up for a first clinical trial in 2022. “It’s a new chapter in T-cell biology,” CEO Zhen Su told BioWorld.
Read More

Financings for Nov. 8, 2021

Nov. 8, 2021

Med-tech firms raising money in public or private financings, including: Beacon Biosignals, Genecentric Therapeutics.


Read More

Financings for Nov. 8, 2021

Nov. 8, 2021
Biopharmas raising money in public or private financings, including: Deepcure, Ensysce, Gyroscope, Hansa, Oramed, Orthogon, Timber.
Read More
Airdoc products, concept image

Airdoc stumbles with Hong Kong IPO

Nov. 5, 2021
By David Ho and Zhang Mengying
Beijing Airdoc Technology Co. Ltd. raised HK$1.67 billion (US$214.8 million) with its IPO on the Hong Kong Exchange (HKEX) on Nov. 5, falling below its expectations of a $500 million raise. Share prices for the artificial intelligence-based (AI) medical imaging firm were priced at HK$75.10 apiece and dropped 3.5% to HK$72.50.
Read More
Previous 1 2 … 431 432 433 434 435 436 437 438 439 … 674 675 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing